Health Canada Approves Generic Semaglutide Injection
Health Canada has given the green light to a generic version of semaglutide injection from Dr. Reddy’s Laboratories, which is equivalent to Ozempic. This marks the first such approval in a G7 country, signaling a major shift in the pharmaceutical landscape.
The decision allows a competing version of the type 2 diabetes treatment to enter a market where Ozempic generated billions in sales last year. More than one million Canadians currently use Ozempic, which has become one of Novo Nordisk’s most commercially important medicines.
Semaglutide, the active ingredient in Ozempic, is also used in the obesity treatment Wegovy. The Canadian approval came after a Novo Nordisk patent related to semaglutide compounds expired. According to reports, the patent lapsed after a required maintenance fee was not paid, ending legal protection earlier than in several other large pharmaceutical markets.
Approval and Standards
Health Canada stated that the approved product met the agency’s standards for safety, quality, and effectiveness. Regulators also mentioned that additional semaglutide submissions remain under review.
This approval reflects growing international interest in generic versions of GLP-1 medicines, a category that has transformed the diabetes and obesity treatment business over the past several years. In India, semaglutide generics have already launched, as patent protection has also expired there. Additional versions are expected in countries such as China, Brazil, Turkey, and South Africa.
Dr. Reddy’s chief executive, Erez Israeli, said in a company press release: “As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets.”
Market Expansion and Competition
The company also highlighted that the approval showcased its experience in peptide development and complex injectable medicines. Health Canada authorized pen presentations containing 2 mg and 4 mg doses at a concentration of 1.34 mg/mL.
Despite this, Novo Nordisk still maintains longer patent protection in several major markets, including the United States. According to reports, the company lists U.S. patent expiry for Ozempic, Wegovy, and Rybelsus in 2032. The Danish drugmaker has also faced rising pressure tied to soaring demand for GLP-1 medicines.
In the United States, semaglutide products experienced supply shortages beginning in 2022, leading some compounding pharmacies to produce alternative versions while supplies remained limited. Novo Nordisk recently adjusted its financial outlook, narrowing its full-year adjusted sales guidance to a decline of 4% to 12% at constant exchange rates, compared with an earlier expectation of a 5% to 13% decline.
Market Changes and Future Outlook
Patent expirations in some countries during 2026 are expected to affect international sales. Semaglutide has become one of the pharmaceutical industry’s most valuable products, helping fuel explosive growth in the global GLP-1 market.
Ozempic, Wegovy, and related medicines have reshaped treatment demand for diabetes and weight management while generating billions in annual revenue for Novo Nordisk. However, the arrival of generic competition in one regulated market does not automatically guarantee lower pharmacy prices or rapid global expansion.
Patent timelines, national regulations, and manufacturing capacity will continue to shape how quickly competitors can enter different countries. Still, the latest approval marks a significant step in the transition of semaglutide from an exclusively branded medicine toward broader generic competition.
